Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders
Open accessThe DOI matches its Crossref record; 142 of the 158 references it cites were found in a registry or an index; 50 of the 167 sources its claims cite were checked for support.
Abstract
Benzodiazepines have proven to be highly effective for treating insomnia and anxiety. Although considered safe when taken for a short period of time, a major risk–benefit dilemma arises in the context of long-term use, relating to addiction, withdrawal symptoms, and potential side effects. For these reasons, benzodiazepines are not recommended for treating chronic sleep disorders, anxiety disorders, nor for people over the age of 65, and withdrawal among long-term users is a public health issue. Indeed, only 5% of patients manage to discontinue using these drugs on their own. Even with the help of a general practitioner, this rate does not exceed 25 to 30% of patients, of which approximately 7% manage to remain drug-free in the long term. Cognitive Behavioral Therapies (CBT) offer a crucial solution to this problem, having been shown to increase abstinence success to 70–80%. This article examines traditional and novel CBT techniques in this regard, such as Acceptance and Commitment Therapy, which address both the underlying condition (insomnia/anxiety) and the substance-related disorder. The theoretical framework and evidence supporting the use of these approaches are reviewed. Finally, current research gaps are discussed, and key research perspectives are proposed. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Overview
CoChat Summary
## TL;DR
This review argues that long-term benzodiazepine withdrawal is difficult and that cognitive behavioral therapy (CBT), including newer forms such as acceptance and commitment therapy (ACT), can improve discontinuation success when paired with tapering. The paper mainly synthesizes prior studies and concludes that CBT should be used before and during deprescribing for patients with insomnia or anxiety disorders.
## Key findings
- The paper states that only 5% of patients discontinue benzodiazepines on their own, and that with a general practitioner the rate rises to 25–30%, with about 7% remaining drug-free long term.
- In the reviewed literature, brief interventions for discontinuation had an overall success rate of 25–40%, versus 5% for waiting list or treatment as usual.
- The paper reports eight RCTs comparing taper alone vs taper plus CBT, plus two publications with long-term outcomes; among these, five out of seven studies showed greater success with CBT plus tapering.
- Specific examples reported for CBT plus tapering include: panic disorder (80% vs 40%, 75% vs 23%, 62.5% vs 12.5% at 6 months), generalized anxiety disorder (75% vs 35% at 12 months), insomnia (85% vs 48% and 70% vs 25% at 12 months), and panic disorder at 24 months (75% vs 30%). For insomnia, relapse was still seen at 5 years, but benefit remained (50% vs 32%).
## Methods
- Narrative review of the theoretical and clinical-trial evidence on CBT and ACT for discontinuing long-term benzodiazepine use in insomnia and anxiety disorders.
- The authors searched Medline, PsycINFO, and the Cochrane Collaboration Central Register of Controlled Trials in November 2020, and also used citations from studies, reviews, and meta-analyses of benzodiazepine-reduction interventions.
- The review synthesized RCTs and meta-analyses on taper programs, CBT, and ACT, with attention to insomnia, anxiety disorders, withdrawal, and abstinence outcomes.
## Limitations
- The paper explicitly states that studies on CBT interventions are scarce: nine RCTs over 30 years of research, and that the number of studies on ACT for benzodiazepine withdrawal is insufficient to establish a recommendation.
- It also states that no study has assessed the effectiveness of ACT on BZD withdrawal as a primary outcome, and that evidence for ACT in this area is limited to one pilot study for insomnia associated with sleeping pill addiction.
- Evident from the text: this is a review, not a new clinical trial, so its conclusions depend on the quality and heterogeneity of the included studies; the paper itself notes that withdrawal programs, follow-up duration, and patient definitions vary greatly across studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
32 Valid · 11 Not valid · 49 Not checked · 43 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“or quadruples (62.5% versus 12.5%) [119] the number of drug-free patients at 6 months.”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 3. Cognitive Behavioral Therapy (CBT) for Discontinuing Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 3.4. Effectiveness of Adding CBT to Taper Programs
What the sources say
- Disputedcites [119] Otto M.W. McHugh R.K. Simon N.M. Farach F.J. Worthington J.J. Pollack M.H. Efficacy of CBT for Benzodiazepine Discontinuation in Patients with Panic Disorder: Further Evaluation Behav. Res. Ther. 2010 48 720 727 10.1016/j.brat.2010.04.002 20546699 PMC5962448 sourceExperimental — accuracy not yet measured
The Results > BZ-Free Status section reports 62.5% benzodiazepine-free with CBT at six months, but 12.5% was the rate for taper plus relaxation, not taper alone. The taper-alone rate was 26.7%, so the stated comparison and “quadruples” description do not match the paper. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6].”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 1. Introduction Benzodiazepines and related drugs (Z-drugs) (BZD) are a class of psychotropic drugs with an effect similar to that of alcohol: they amplify the activity of GABA-A receptors, producing hypnotic, anxiolytic, muscle relaxant, anticonvulsant, and amnesic effects [1]. BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6]. Their duration of action depends on their elimination half-life (the time taken by the body to eliminate half of the dose), which is classified as short (1–12 h), medium (12–40 h), and long (>40 h). These substances require a prescription and are intended to be used under the surveillance of a medical practitioner. They are recommended by health authorities as a short-term treatment [7] and are therefore not intented to be used for the treatment of chronic anxiety or insomnia. However, such prescription recommendations, alone, have not prevented their widespread overuse, and the subsequent development of psychological addictions. This article aims to (i) describe the global epidemiology of BZD use with a particular focus on the situation in France, and the issues associated with long-term BZD use such as side effects, withdrawal syndrome and ecological impact, (ii) review the public health strategies proposed in European countries to limit the use of BZD as well as the therapeutic interventions available for promoting BZD withdrawal, and (iii) provide an up-to-date overview of the theoretical framework and the clinical trial-based evidence supporting the use of traditional and new generations of Cognitive and Behavioral Therapy (CBT) for successful long-term BZD use cessation, with a specific interest in Acceptance and Commitment Therapy (ACT).
What the sources say
- Partly supportedcites [2] Slee A. Nazareth I. Bondaronek P. Liu Y. Cheng Z. Freemantle N. Pharmacological Treatments for Generalised Anxiety Disorder: A Systematic Review and Network Meta-Analysis Lancet 2019 393 768 777 10.1016/S0140-6736(18)31793-8 30712879 sourceExperimental — accuracy not yet measured
The Discussion says benzodiazepines have a good effect on reducing anxiety symptoms in the network analysis. However, the analysis covers generalised anxiety disorder; it does not establish effectiveness across anxiety disorders generally. No page number is available in our copy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [3] Bandelow B. Reitt M. Röver C. Michaelis S. Görlich Y. Wedekind D. Efficacy of Treatments for Anxiety Disorders: A Meta-Analysis Int. Clin. Psychopharmacol. 2015 30 183 192 10.1097/YIC.0000000000000078 25932596 source
- Supportedcites [4] Stahl S.M. Don’t Ask, Don’t Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder J. Clin. Psychiatry 2002 63 756 757 10.4088/JCP.v63n0901 12363113 source
The 'Combining Independent Mechanisms to Enhance Therapeutic Results' section says benzodiazepines may provide rapid relief, boost early treatment efficacy, and relieve breakthrough anxiety. This supports the attributed claim that they are effective for treating anxiety disorders, while acknowledging limitations. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These symptoms are more severe following withdrawal from short rather than long half-life BZDs [39,40,41,42,43].”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 2. Benzodiazepine Use and Abuse > 2.2. Low Benefit-to-Risk Ratio
What the sources say
- Not checked — no full text of the sourcecites [39] Lapierre Y.D. Benzodiazepine Withdrawal Can. J. Psychiatry 1981 26 93 95 10.1177/070674378102600203 6114793 source
- Partly supportedcites [40] Morgan K. Oswald I. Anxiety Caused by a Short-Life Hypnotic Br. Med. J. 1982 284 942 10.1136/bmj.284.6320.942 6121606 PMC1496517 sourceExperimental — accuracy not yet measured
The Subjects, methods, and results section reports that anxiety peaked sooner after withdrawal of the shorter-lived triazolam than after withdrawal of loprazolam. The Comment likewise says faster elimination produces earlier rebound, but neither passage establishes that withdrawal symptoms are generally more severe with short- than long-half-life benzodiazepines. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [41] Soldatos C.R. Dikeos D.G. Whitehead A. Tolerance and Rebound Insomnia with Rapidly Eliminated Hypnotics: A Meta-Analysis of Sleep Laboratory Studies Int. Clin. Psychopharmacol. 1999 14 287 303 10.1097/00004850-199909000-00004 10529072 source
- Not checked — no full text of the sourcecites [42] Kales A. Soldatos C.R. Bixler E.O. Kales J.D. Rebound Insomnia and Rebound Anxiety: A Review Pharmacology 1983 26 121 137 10.1159/000137794 6132413 source
- Not checked — no full text of the sourcecites [43] Gillin J. Spinweber C. Johnson L. Rebound Insomnia: A Critical Review J. Clin. Psychopharmacol. 1989 9 161 172 10.1097/00004714-198906000-00002 2567741 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6].”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 1. Introduction Benzodiazepines and related drugs (Z-drugs) (BZD) are a class of psychotropic drugs with an effect similar to that of alcohol: they amplify the activity of GABA-A receptors, producing hypnotic, anxiolytic, muscle relaxant, anticonvulsant, and amnesic effects [1]. BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6]. Their duration of action depends on their elimination half-life (the time taken by the body to eliminate half of the dose), which is classified as short (1–12 h), medium (12–40 h), and long (>40 h). These substances require a prescription and are intended to be used under the surveillance of a medical practitioner. They are recommended by health authorities as a short-term treatment [7] and are therefore not intented to be used for the treatment of chronic anxiety or insomnia. However, such prescription recommendations, alone, have not prevented their widespread overuse, and the subsequent development of psychological addictions. This article aims to (i) describe the global epidemiology of BZD use with a particular focus on the situation in France, and the issues associated with long-term BZD use such as side effects, withdrawal syndrome and ecological impact, (ii) review the public health strategies proposed in European countries to limit the use of BZD as well as the therapeutic interventions available for promoting BZD withdrawal, and (iii) provide an up-to-date overview of the theoretical framework and the clinical trial-based evidence supporting the use of traditional and new generations of Cognitive and Behavioral Therapy (CBT) for successful long-term BZD use cessation, with a specific interest in Acceptance and Commitment Therapy (ACT).
What the sources say
- Not checked — no full text of the sourcecites [5] Morgan K. Psychological and Pharmacological Treatments for Insomnia: Blending for Patient Benefit Sleep Med. Rev. 2021 56 101415 10.1016/j.smrv.2020.101415 33529781 source
- Supportedcites [6] Buscemi N. Vandermeer B. Friesen C. Bialy L. Tubman M. Ospina M. Klassen T.P. Witmans M. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTs J. Gen. Intern. Med. 2007 22 1335 1350 10.1007/s11606-007-0251-z 17619935 PMC2219774 source
The Abstract concludes that benzodiazepines are effective treatments for chronic insomnia. The Discussion likewise reports effectiveness, while noting that the evidence is most relevant to short-term treatment of chronic insomnia. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nevertheless, two reviews show no added value of melatonin substitution [66,67] and, to the best of our knowledge, arguments regarding the benefit of diazepam substitution are mostly theoretical (not evidence-based).”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 2. Benzodiazepine Use and Abuse > 2.3. Recommendations for Use
What the sources say
- Partly supportedcites [66] Vissers F.H.J.A. Knipschild P.G. Crebolder H.F.J.M. Is Melatonin Helpful in Stopping the Long-Term Use of Hypnotics? A Discontinuation Trial Pharm. World Sci. 2007 29 641 646 10.1007/s11096-007-9118-y 17610043 PMC2039831 sourceExperimental — accuracy not yet measured
The Results report nearly identical one-year benzodiazepine discontinuation rates with melatonin and placebo (8/20 versus 7/18), with no significant difference. But this source is a discontinuation trial, not a review, and its Abstract Conclusion says the findings are inconclusive, particularly because the participants' average benzodiazepine dose was low. It therefore supports a lack of demonstrated added benefit in this trial, not the claim that reviews establish no added value generally. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [67] Wright A. Diebold J. Otal J. Stoneman C. Wong J. Wallace C. Duffett M. The Effect of Melatonin on Benzodiazepine Discontinuation and Sleep Quality in Adults Attempting to Discontinue Benzodiazepines: A Systematic Review and Meta-Analysis Drugs Aging 2015 32 1009 1018 10.1007/s40266-015-0322-5 26547856 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
47 more claims · 9 with their cited sources checked
Create a free account to see all 135 claims and to verify the 4 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 46
Citations
Cites
The Transtheoretical Model of Health Behavior Change.
Prochaska, J. O., & Velicer, W. F. (1997) · American Journal of Health Promotion · doi:10.4278/0890-1171-12.1.38 · Cited by 7,782
Hayes, S. C., Wilson, K. G., Gifford, E. V., Follette, V. M., & Strosahl, K. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.64.6.1152 · Cited by 3,595
Hoffman, S. G., & Smits, J. A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0415 · Cited by 1,420
Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004)
Morin, C. M., Bootzin, R. R., Buysse, D. J., Edinger, J. D., Espie, C. A., & Lichstein, K. L. (2006) · Sleep · doi:10.1093/sleep/29.11.1398 · Cited by 1,345
Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural Populations
Brodin, T., Fick, J., Jonsson, M., & Klaminder, J. (2013) · Science · doi:10.1126/science.1226850 · Cited by 850 · cited 1×
“A study published in the Science journal reveals that concentrations of benzodiazepines in water effluents affect the behavior of fish and disrupt the food chain, with potentially serious evolutionary consequences [48].”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Hayes, S. C. (2016) · Behavior Therapy · doi:10.1016/j.beth.2016.11.006 · Cited by 785
Efficacy of the third wave of behavioral therapies: A systematic review and meta- analysis
Öst, L.-G. (2008) · Behaviour Research and Therapy · doi:10.1016/j.brat.2007.12.005 · Cited by 727
Zachariae, R., Lyby, M. S., Ritterband, L. M., & O'Toole, M. S. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.10.004 · Cited by 704 · cited 1×
“CBT-I is recognised as being the treatment of choice for insomnia [93], both in isolated form or as a comorbidity [94], in psychiatric populations [95], among the elderly [96,97], and delivered remotely [98].”
BackgroundTannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.949 · Cited by 665
Behavioral treatment of panic disorder
Barlow, D. H., Craske, M. G., Cerny, J. A., & Klosko, J. S. (1989) · Behavior Therapy · doi:10.1016/s0005-7894(89)80073-5 · Cited by 627
Sivertsen, B., Omvik, S., Pallesen, S., Bjorvatn, B., Havik, O. E., Kvale, G., Nielsen, G. H., & Nordhus, I. H. (2006) · JAMA · doi:10.1001/jama.295.24.2851 · Cited by 589
Jacobs, G. D., Pace-Schott, E. F., Stickgold, R., & Otto, M. W. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.17.1888 · Cited by 579
Efficacy of treatments for anxiety disorders: a meta-analysis
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000078 · Cited by 555
Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303061 · Cited by 531 · cited 1×
“increased by more than 300% between 2004 and 2011 [18].”
BackgroundPsychological treatment of generalized anxiety disorder: A meta-analysis
Cuijpers, P., Sijbrandij, M., Koole, S., Huibers, M., Berking, M., & Andersson, G. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.01.002 · Cited by 527
The epidemiology of benzodiazepine misuse: A systematic review*
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.033 · Cited by 479 · cited 1×
“BZD misuse is reported in approximately 2% of the general adult population [10,11].”
BackgroundThought suppression and psychopathology
Purdon, C. (1999) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(98)00200-9 · Cited by 454
The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTs
Buscemi, N., Vandermeer, B., Friesen, C., Bialy, L., Tubman, M., Ospina, M., Klassen, T. P., & Witmans, M. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0251-z · Cited by 448 · cited 1×
“BZDs are effective in the treatment of anxiety disorders [2–4] and insomnia [5,6].”
BackgroundTherapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults
Olthuis, J. V., Watt, M. C., Bailey, K., Hayden, J. A., & Stewart, S. H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011565.pub2 · Cited by 390
Improving sleep with mindfulness and acceptance: a metacognitive model of insomnia
Ong, J. C., Ulmer, C. S., & Manber, R. (2012) · Behaviour Research and Therapy · doi:10.1016/j.brat.2012.08.001 · Cited by 376
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Thought Suppression and Psychopathology
Najmi, S., & Wegner, D. M. (2015) · Handbook of Approach and Avoidance Motivation · doi:10.4324/9780203888148.ch26 · Cited by 369
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367 · cited 1×
“Benzodiazepine withdrawal syndrome may develop at any time, usually around 4–7 days but up to 3 weeks after stopping long-acting BZDs [45], and within 48 h after reducing intake of short-acting BZDs [46].”
BackgroundTaylor, D. J., & Pruiksma, K. E. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2014.902808 · Cited by 359 · cited 1×
“CBT-I is recognised as being the treatment of choice for insomnia [93], both in isolated form or as a comorbidity [94], in psychiatric populations [95], among the elderly [96,97], and delivered remotely [98].”
BackgroundMorin, C. M., Bastien, C., Guay, B., Radouco-Thomas, M., Leblanc, J., & Vallières, A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.332 · Cited by 348 · cited 5×
“The CBT used in these protocols, with the exception of one study [121], principally targeted the conditions that initially led to the misuse of BZD: insomnia in people over 50 years old [33,122,123], panic disorders [118–120], or generalized anxiety disorder (GAD) [108,124].”
BackgroundMethodInfluentialLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Cognitive Behavioral Therapy in Persons with Comorbid Insomnia: A Meta-Analysis
Geiger-Brown, J. M., Rogers, V. E., Liu, W., Ludeman, E. M., Downton, K. D., & Diaz-Abad, M. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.11.007 · Cited by 331 · cited 1×
“CBT-I is recognised as being the treatment of choice for insomnia [93], both in isolated form or as a comorbidity [94], in psychiatric populations [95], among the elderly [96,97], and delivered remotely [98].”
BackgroundKurko, T. A. T., Saastamoinen, L. K., Tähkäpää, S., Tuulio-Henriksson, A., Taiminen, T., Tiihonen, J., Airaksinen, M. S., & Hietala, J. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.003 · Cited by 280 · cited 1×
“Since addiction occurs within the first month of use [12], the legal prescription period is often exceeded [9,13,14].”
BackgroundAn initial meta-analysis of acceptance and commitment therapy for treating substance use disorders
Lee, E. B., An, W., Levin, M. E., & Twohig, M. P. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.004 · Cited by 271
Gradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271 · cited 4×
“By encouraging the patient to take an active role, this goal-oriented approach increases compliance with the withdrawal program and reduces the risk of early relapse [38,44,86,87,91,116].”
BackgroundInfluential(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
A systematic review of non-pharmacological therapies for sleep problems in later life
Montgomery, P. (2004) · Sleep Medicine Reviews · doi:10.1016/s1087-0792(03)00026-1 · Cited by 260 · cited 1×
“CBT-I is recognised as being the treatment of choice for insomnia [93], both in isolated form or as a comorbidity [94], in psychiatric populations [95], among the elderly [96,97], and delivered remotely [98].”
BackgroundBenzodiazepines: Risks and Benefits. A Reconsideration
Baldwin, D. S., Aitchison, K., Bateson, A., Curran, H. V., Davies, S., Leonard, B., Nutt, D. J., Stephens, D. N., & Wilson, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503509 · Cited by 249 · cited 2×
“They have been shown to be effective in the acute treatment of generalized anxiety disorder, social anxiety, panic disorder, and insomnia [8].”
BackgroundCognitive behavioural interventions for sleep problems in adults aged 60+
Montgomery, P., & Dennis, J. A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003161 · Cited by 231 · cited 1×
“CBT-I is recognised as being the treatment of choice for insomnia [93], both in isolated form or as a comorbidity [94], in psychiatric populations [95], among the elderly [96,97], and delivered remotely [98].”
BackgroundEffectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212 · cited 1×
“However, some meta-analyses show that CBT at least doubles the abstinence rate compared to a simple withdrawal program [82,127,128].”
BackgroundAcceptance and Commitment Therapy in the treatment of anxiety: A systematic review
Swain, J., Hancock, K., Hainsworth, C., & Bowman, J. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.07.002 · Cited by 207
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar, R. C. O., Couvée, J. E., Van Balkom, A. J. L. M., Mulder, P. G. H., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.189.3.213 · Cited by 205
Gustavsen, I., Bramness, J. G., Skurtveit, S., Engeland, A., Neutel, I., & Mørland, J. (2008) · Sleep Medicine · doi:10.1016/j.sleep.2007.11.011 · Cited by 201 · cited 1×
“In the short term, they increase daytime sleepiness and the risk of road accidents [26,27].”
BackgroundRebound Insomnia and Rebound Anxiety: A Review
Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (2008) · Pharmacology · doi:10.1159/000137794 · Cited by 198
Reeve, E., Ong, M., Wu, A., Jansen, J., Petrovic, M., & Gnjidic, D. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2257-8 · Cited by 192
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
(2003) · Europe PMC (PubMed Central) · Cited by 176
Bashir, K., King, M., & Ashworth, M. J. (1994) · Europe PMC (PubMed Central) · Cited by 163
Fourrier, A., Letenneur, L., Dartigues, J., Moore, N., & Bégaud, B. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100326 · Cited by 158 · cited 2×
“They can cause muscle weakness, loss of coordination and gait problems, dizziness, confusion, speech problems, and even anterograde amnesia [15].”
BackgroundHall, J., Kellett, S., Berrios, R., Bains, M. K., & Scott, S. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.06.006 · Cited by 157
Gould, R. L., Coulson, M. C., Patel, N., Highton-Williamson, E., & Howard, R. J. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.126003 · Cited by 156 · cited 1×
“The last two meta-analyses on the topic [84,85] emphasise the effectiveness of supervised withdrawal supported by psychotherapy and in particular the addition of cognitive behavioral therapies.”
BackgroundEvaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice.
Cormack, M., Sweeney, K., Hughes-Jones, H., & Foot, G. A. (1994) · Europe PMC (PubMed Central) · Cited by 154
Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., Van Den Hoogen, J. M., & Zitman, F. G. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.498 · Cited by 154
Soldatos, C. R., Dikeos, D. G., & Whitehead, A. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199909000-00004 · Cited by 154
Does Cognitive Behavior Therapy Assist Slow-Taper Alprazolam Discontinuation in Panic Disorder?
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.876 · Cited by 153
The Epidemiology of Long-Term Benzodiazepine Use
Neutel, C. I. (2005) · International Review of Psychiatry · doi:10.1080/09540260500071863 · Cited by 148 · cited 1×
“BZD misuse is reported in approximately 2% of the general adult population [10,11].”
BackgroundThe Benzodiazepine–Dementia Disorders Link: Current State of Knowledge
Pariente, A., de Gage, S. B., Moore, N. D., & Bégaud, B. (2015) · CNS Drugs · doi:10.1007/s40263-015-0305-4 · Cited by 144
Psychosocial interventions for benzodiazepine harmful use, abuse or dependence
Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009652.pub2 · Cited by 142
Pompoli, A., Furukawa, T. A., Imai, H., Tajika, A., Efthimiou, O., & Salanti, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011004.pub2 · Cited by 142
Anxiety caused by a short-life hypnotic.
Morgan, K., & Oswald, I. (1982) · BMJ · doi:10.1136/bmj.284.6320.942 · Cited by 137
Farrell, B., Pottie, K., Rojas-Fernandez, C. H., Bjerre, L. M., Thompson, W., & Welch, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161248 · Cited by 134 · cited 1×
“In France [52,53] and in Canada [54,55], awareness campaigns have been carried out and withdrawal guides distributed.”
BackgroundPetitjean, S., Ladewig, D., Meier, C. R., Amrein, R., & Wiesbeck, G. A. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328105e0f2 · Cited by 132 · cited 1×
“5% of patients have been using BZD beyond 12 months, and like in France, this overuse tends to increase with age [16].”
BackgroundSmout, M. F., Longo, M., Harrison, S., Minniti, R., Wickes, W., & White, J. M. (2010) · Substance Abuse · doi:10.1080/08897071003641578 · Cited by 129
Mugunthan, K., McGuire, T., & Glasziou, P. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x593857 · Cited by 123
Gosselin, P., Ladouceur, R., Morin, C. M., Dugas, M. J., & Baillargeon, L. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.5.908 · Cited by 122
Wu, R., Bao, J., Zhang, C., Deng, J., & Long, C. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000092892 · Cited by 120
Benzodiazepine-Like Hypnotics and the Associated Risk of Road Traffic Accidents
Orriols, L., Philip, P., Moore, N., Castot, A., Gadegbeku, B., Delorme, B., Mallaret, M., & Lagarde, E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.3 · Cited by 118 · cited 1×
“In the short term, they increase daytime sleepiness and the risk of road accidents [26,27].”
BackgroundCognitive Behaviour Therapy for Health Anxiety: A Systematic Review and Meta-Analysis
Cooper, K., Gregory, J. D., Walker, I., Lambe, S., & Salkovskis, P. M. (2017) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465816000527 · Cited by 118
Ironic effects of trying to relax under stress
Wegner, D. M., Broome, A., & Blumberg, S. J. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(96)00078-2 · Cited by 117
The Problems of Long-Term Treatment With Benzodiazepines and Related Substances
Janhsen, K., Roser, P., & Hoffmann, K. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0001 · Cited by 114 · cited 1×
“The prescription and use of BZDs has been under scrutiny for over 40 years [23] due to their many side effects [8,24,25].”
BackgroundBenzodiazepines: More Behavioural Addiction than Dependence
de las Cuevas, C., Sanz, E., & de la Fuente, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1376-8 · Cited by 113 · cited 1×
“Since addiction occurs within the first month of use [12], the legal prescription period is often exceeded [9,13,14].”
BackgroundRickels, K., DeMartinis, N., García-España, F., Greenblatt, D. J., Mandos, L. A., & Rynn, M. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1973 · Cited by 110 · cited 1×
“By encouraging the patient to take an active role, this goal-oriented approach increases compliance with the withdrawal program and reduces the risk of early relapse [38,44,86,87,91,116].”
BackgroundInternet-Delivered Acceptance and Commitment Therapy for Anxiety Treatment: Systematic Review.
Kelson, J., Rollin, A., Ridout, B., & Campbell, A. (2019) · Journal of Medical Internet Research · doi:10.2196/12530 · Cited by 107
Murphy, S. M., & Tyrer, P. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.511 · Cited by 104 · cited 2×
“By encouraging the patient to take an active role, this goal-oriented approach increases compliance with the withdrawal program and reduces the risk of early relapse [38,44,86,87,91,116].”
BackgroundBricker, J. B., Bush, T., Zbikowski, S. M., Mercer, L. D., & Heffner, J. L. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntu102 · Cited by 100
Gorgels, W. J. M. J., Oude Voshaar, R. C., Mol, A. J. J., van de Lisdonk, E. H., van Balkom, A. J. L. M., van den Hoogen, H. J. M., Mulder, J., Breteler, M. H. M., & Zitman, F. G. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.09.001 · Cited by 100 · cited 1×
“For example, one study reported an abstinence rate of 24% at 6 months following a simple letter from the prescribing doctor [73], and this rate fell to 7% ten years later [74].”
BackgroundRebound Insomnia: A Critical Review
GILLIN, J. C., SPINWEBER, C. L., & JOHNSON, L. C. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198906000-00002 · Cited by 99
Otto, M. W., McHugh, R. K., Simon, N. M., Farach, F. J., Worthington, J. J., & Pollack, M. H. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.04.002 · Cited by 95
Morin, C. M., Bélanger, L., Bastien, C., & Vallières, A. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2003.12.002 · Cited by 91
Natsky, A. N., Vakulin, A., Chai-Coetzer, C. L., Lack, L., McEvoy, R. D., Lovato, N., Sweetman, A., Gordon, C. J., Adams, R. J., & Kaambwa, B. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101351 · Cited by 91
Stahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88 · cited 1×
“They are fast-acting and well-tolerated substances [4] which provide immediate relief.”
BackgroundKishita, N., & Laidlaw, K. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.01.003 · Cited by 87
Seizure following sudden zolpidem withdrawal
Cubała, W. J., & Landowski, J. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.07.009 · Cited by 86
Risk versus risk: a review of benzodiazepine reduction in older adults
Paquin, A. M., Zimmerman, K., & Rudolph, J. L. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.925444 · Cited by 82 · cited 1×
“The last two meta-analyses on the topic [84,85] emphasise the effectiveness of supervised withdrawal supported by psychotherapy and in particular the addition of cognitive behavioral therapies.”
BackgroundGonzález-Menéndez, A., Fernández, P., Rodríguez, F., & Villagrá, P. (2014) · International Journal of Clinical and Health Psychology · doi:10.1016/s1697-2600(14)70033-x · Cited by 81
The effect of acceptance and commitment therapy on insomnia and sleep quality: A systematic review
Salari, N., Khazaie, H., Hosseinian-Far, A., Khaledi-Paveh, B., Ghasemi, H., Mohammadi, M., & Shohaimi, S. (2020) · BMC Neurology · doi:10.1186/s12883-020-01883-1 · Cited by 78
Murphy, S. M., Owen, R., & Tyrer, P. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.4.529 · Cited by 77 · cited 1×
“Spontaneous attempts to discontinue consumption cause withdrawal syndrome in 50–80% of users [37,38], characterized by increased insomnia or anxiety (i.”
BackgroundHypnotic taper with or without self-help treatment of insomnia: A randomized clinical trial.
Belleville, G., Guay, C., Guay, B., & Morin, C. M. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.2.325 · Cited by 77 · cited 1×
“These can take the form of a discussion with the prescribing doctor [68–72], a simple letter from the doctor recommending that the treatment should be stopped or gradually reduced [70,71,73–76], therapeutic education sessions with a nurse [65], or an educational brochure about withdrawal distributed by the pharmacist…”
BackgroundHeather, N., Bowie, A., Ashton, H., McAvoy, B., Spencer, I., Brodie, J., & Giddings, D. (2004) · Addiction Research & Theory · doi:10.1080/1606635310001634528 · Cited by 77
Screening of Benzodiazepines in Thirty European Rivers
Fick, J., Brodin, T., Heynen, M., Klaminder, J., Jonsson, M., Grabicova, K., Randak, T., Grabic, R., Kodes, V., Slobodnik, J., et al. (2017) · Chemosphere · doi:10.1016/j.chemosphere.2017.02.126 · Cited by 76 · cited 1×
“Excessive concentrations of these drugs in waterways are considered to be a threat to aquatic ecosystems [47].”
BackgroundThe Use of Acceptance and Commitment Therapy in Substance Use Disorders: A Review of Literature
Osaji, J., Ojimba, C., & Ahmed, S. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4311 · Cited by 74
Bruce, T. J., Spiegel, D. A., & Hegel, M. T. (1999) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.67.1.151 · Cited by 69
Withdrawal from long-term benzodiazepine use: randomised trial in family practice.
(2006) · PubMed Central · Cited by 67
Cantopher, T., Olivieri, S., Cleave, N., & Edwards, J. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.156.3.406 · Cited by 67 · cited 1×
“Benzodiazepine withdrawal syndrome may develop at any time, usually around 4–7 days but up to 3 weeks after stopping long-acting BZDs [45], and within 48 h after reducing intake of short-acting BZDs [46].”
BackgroundCheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66 · cited 1×
“Benzodiazepines and related drugs (Z-drugs) (BZD) are a class of psychotropic drugs with an effect similar to that of alcohol: they amplify the activity of GABA-A receptors, producing hypnotic, anxiolytic, muscle relaxant, anticonvulsant, and amnesic effects [1].”
BackgroundSCHWEIZER, E., RICKELS, K., De MARTINIS, N., CASE, G., & GARCÍA-ESPAÑA, F. (1998) · Psychological Medicine · doi:10.1017/s0033291798006540 · Cited by 60 · cited 2×
“By encouraging the patient to take an active role, this goal-oriented approach increases compliance with the withdrawal program and reduces the risk of early relapse [38,44,86,87,91,116].”
BackgroundMultifocal Cognitive Dysfunction in High-Dose Benzodiazepine Users: A Cross-Sectional Study
Federico, A., Tamburin, S., Maier, A., Faccini, M., Casari, R., Morbioli, L., & Lugoboni, F. (2017) · Neurological Sciences · doi:10.1007/s10072-016-2732-5 · Cited by 60 · cited 2×
“Long-term use may result in altered sleep structure (reduced slow wave sleep), as well as cognitive dysfunction (especially with high doses: reduced attentional resources and impaired verbal and visuospatial memory, working memory, and executive functions) [25].”
BackgroundSalonoja, M., Salminen, M., Aarnio, P., Vahlberg, T., & Kivela, S. L. (2010) · Age and Ageing · doi:10.1093/ageing/afp255 · Cited by 59
Bobes, J., Rubio, G., Terán, A., Cervera, G., López-Gómez, V., Vilardaga, I., & Pérez, M. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2010.12.004 · Cited by 57
Lappalainen, P., Langrial, S., Oinas-Kukkonen, H., Muotka, J., & Lappalainen, R. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.04.001 · Cited by 57
Takaesu, Y., Utsumi, T., Okajima, I., Shimura, A., Kotorii, N., Kuriyama, K., Yamashita, H., Suzuki, M., Watanabe, N., & Mishima, K. (2019) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.101214 · Cited by 57
Craner, J. R., Lake, E. S., Bancroft, K. A., & George, L. L. (2020) · Pain Practice · doi:10.1111/papr.12824 · Cited by 55
Lähteenmäki, R., Puustinen, J., Vahlberg, T., Lyles, A., Neuvonen, P. J., Partinen, M., Räihä, I., & Kivelä, S.-L. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12294 · Cited by 54
Psychological Treatment of Hypnotic-Dependent Insomnia in a Primarily Older Adult Sample
Lichstein, K. L., Nau, S. D., Wilson, N. M., Aguillard, R. N., Lester, K. W., Bush, A. J., & McCrae, C. S. (2013) · Behaviour Research and Therapy · doi:10.1016/j.brat.2013.09.006 · Cited by 54
Benzodiazepine Withdrawal Seizures: Analysis of 48 Case Reports
Fialip, J., Aumaitre, O., Eschalier, A., Maradeix, B., Dordain, G., & Lavarenne, J. (1987) · Clinical Neuropharmacology · doi:10.1097/00002826-198712000-00005 · Cited by 53 · cited 1×
“Some studies have reported epileptic seizures [57] following an abrupt discontinuation of BZDs, and hence recommend a gradual reduction over at least 6 days to avoid convulsions [58].”
BackgroundTen Wolde, G. B., Dijkstra, A., Van Empelen, P., Van Den Hout, W., Knuistingh Neven, A., & Zitman, F. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02141.x · Cited by 52 · cited 1×
“These can take the form of a discussion with the prescribing doctor [68–72], a simple letter from the doctor recommending that the treatment should be stopped or gradually reduced [70,71,73–76], therapeutic education sessions with a nurse [65], or an educational brochure about withdrawal distributed by the pharmacist…”
BackgroundBenzodiazepine withdrawal seizures: analysis of 48 case reports.
Fialip, J., Aumaître, O., Eschalier, A., Maradeix, B., Dordain, G., & Lavarenne, J. (1987) · PubMed · Cited by 50
Marra, E. M., Mazer‐Amirshahi, M., Brooks, G., van den Anker, J., May, L., & Pines, J. M. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13666 · Cited by 47 · cited 1×
“However, the link between BZD and the development of neurodegenerative diseases is still questioned [34,35].”
BackgroundChapoutot, M., Peter‐Derex, L., Schoendorff, B., Faivre, T., Bastuji, H., & Putois, B. (2021) · Journal of Sleep Research · doi:10.1111/jsr.13199 · Cited by 47
Self-citationO'Connor, K., Marchand, A., Brousseau, L., Aardema, F., Mainguy, N., Landry, P., Savard, P., Léveillé, C., Lafrance, V., Boivin, S., et al. (2008) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.556 · Cited by 44
Discontinuation of Long-Term Benzodiazepine Use: 10-Year Follow-Up
de Gier, N., Gorgels, W., Lucassen, P., Oude Voshaar, R., Mulder, J., & Zitman, F. (2011) · Family Practice · doi:10.1093/fampra/cmq113 · Cited by 43 · cited 1×
“For example, one study reported an abstinence rate of 24% at 6 months following a simple letter from the prescribing doctor [73], and this rate fell to 7% ten years later [74].”
BackgroundWright, A., Diebold, J., Otal, J., Stoneman, C., Wong, J., Wallace, C., & Duffett, M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0322-5 · Cited by 43 · cited 1×
“Nevertheless, two reviews show no added value of melatonin substitution [66,67] and, to the best of our knowledge, arguments regarding the benefit of diazepam substitution are mostly theoretical (not evidence-based).”
BackgroundProcesses in acceptance and commitment therapy and the rehabilitation of chronic fatigue.
Jacobsen, H. B., Kallestad, H., Landrø, N. I., Borchgrevink, P. C., & Stiles, T. C. (2017) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12363 · Cited by 43
Baandrup, L., Lindschou, J., Winkel, P., Gluud, C., & Glenthoj, B. Y. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1048725 · Cited by 42
Petrovic, M., Pevernagie, D., Mariman, A., Van Maele, G., & Afschrift, M. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0387-4 · Cited by 42
Kunz, D., Bineau, S., Maman, K., Milea, D., & Toumi, M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.638284 · Cited by 37
Is Melatonin Helpful in Stopping the Long-Term Use of Hypnotics? A Discontinuation Trial
Vissers, F. H. J. A., Knipschild, P. G., & Crebolder, H. F. J. M. (2007) · Pharmacy World & Science · doi:10.1007/s11096-007-9118-y · Cited by 36 · cited 1×
“Nevertheless, two reviews show no added value of melatonin substitution [66,67] and, to the best of our knowledge, arguments regarding the benefit of diazepam substitution are mostly theoretical (not evidence-based).”
BackgroundZolpidem dependence and withdrawal seizure--report of two cases.
Wang, L., Ree, S., Chu, C.-L., & Juang, Y. (2011) · PubMed · Cited by 35
The role of insomnia in the treatment of chronic fatigue.
Kallestad, H., Jacobsen, H. B., Landrø, N. I., Borchgrevink, P. C., & Stiles, T. C. (2015) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2014.11.022 · Cited by 35
Fact: Antidepressants and anxiolytics are not safe during pregnancy
Campagne, D. M. (2007) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2007.06.010 · Cited by 33 · cited 1×
“BZD use should be avoided by pregnant and breastfeeding women [31].”
BackgroundFactors Predicting Long-Term Outcome after Chronic Benzodiazepine Therapy
Holton, A., Riley, P., & Tyrer, P. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90109-j · Cited by 33
Takeshima, M., Otsubo, T., Funada, D., Murakami, M., Usami, T., Maeda, Y., Yamamoto, T., Matsumoto, T., Shimane, T., Aoki, Y., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13195 · Cited by 31
SANCHEZ‐CRAIG, M., CAPPELL, H., BUSTO, U., & KAY, G. (1987) · British Journal of Addiction · doi:10.1111/j.1360-0443.1987.tb00434.x · Cited by 30
Psychological Distress and Adaptational Problems Associated with Discontinuation of Benzodiazepines
O’Connor, K., Bélanger, L., Marchand, A., Dupuis, G., Elie, R., & Boyer, R. (1999) · Addictive Behaviors · doi:10.1016/s0306-4603(98)00107-5 · Cited by 29
Long-Term Outcome after Benzodiazepine Withdrawal Treatment in Subjects with Complicated Dependence
Vorma, H., Naukkarinen, H., Sarna, S., & Kuoppasalmi, K. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00014-0 · Cited by 26
Lapierre, Y. D. (1981) · The Canadian Journal of Psychiatry · doi:10.1177/070674378102600203 · Cited by 26
Withdrawal from benzodiazepines by initially switching to zopiclone
Shapiro, C., Sherman, D., & Peck, D. (1995) · European Psychiatry · doi:10.1016/0924-9338(96)80096-4 · Cited by 25
Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain
Lopez-Peig, C., Mundet, X., Casabella, B., del Val, J. L., Lacasta, D., & Diogene, E. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-684 · Cited by 25
Marynak, K., Xu, X., Wang, X., Holmes, C. B., Tynan, M. A., & Pechacek, T. F. (2016) · Public Health Reports · doi:10.1177/0033354916662211 · Cited by 24 · cited 1×
“Increasing the cost of these medications is another strategy to reduce their rate of abuse, as was done with tobacco [51].”
BackgroundSubramanian, S., Hesselbacher, S. E., Nye, P. A., Aiyer, A., & Surani, S. (2021) · Sleep And Breathing · doi:10.1007/s11325-021-02331-1 · Cited by 24 · cited 1×
“Given the high prevalence of sleep apnea as a comorbidity in insomnia disorders [22], systematically responding to sleep complaints with benzodiazepine prescriptions should be avoided.”
BackgroundPredictors of benzodiazepine discontinuation in subjects manifesting complicated dependence
VORMA, H., NAUKKARINEN, H. H., SARNA, S. J., & KUOPPASALMI, K. I. (2005) · Substance Use & Misuse · doi:10.1081/ja-200052433 · Cited by 22
The Long-Term Outcome of a Benzodiazepine Discontinuation Programme in Depressed Outpatients
Couvée, J. E., Timmermans, M. A. Y., & Zitman, F. G. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00330-5 · Cited by 20 · cited 1×
“Insomnia is a notable symptom of withdrawal syndromes and a factor of relapse as emphasized by many studies [38,88,90].”
BackgroundDiscontinuing Benzodiazepines: Best Practices
Guaiana, G., & Barbui, C. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000032 · Cited by 18 · cited 1×
“The prescription and use of BZDs has been under scrutiny for over 40 years [23] due to their many side effects [8,24,25].”
BackgroundAcceptance-Based Behavioural Treatment for Insomnia in Chronic Pain: A Clinical Pilot Study
Zetterqvist, V., Grudin, R., Rickardsson, J., Wicksell, R. K., & Holmström, L. (2018) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2018.07.003 · Cited by 17
Allary, A., Proulx-Tremblay, V., Bélanger, C., Hudon, C., Marchand, A., O'Connor, K., Pérodeau, G., Roberge, P., Tannenbaum, C., Vasiliadis, H.-M., et al. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.106195 · Cited by 17
Vethe, D., Kallestad, H., Jacobsen, H. B., Landrø, N. I., Borchgrevink, P. C., & Stiles, T. C. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01764 · Cited by 16
Orriols, L., Gbaguidi, G. N., Contrand, B., Gadegbeku, B., & Lagarde, E. (2019) · Injury Epidemiology · doi:10.1186/s40621-019-0209-8 · Cited by 13 · cited 1×
“The proportion of BZD-using drivers involved in accidents has also increased over the past 10 years [19].”
BackgroundPersonality and Symptom Sensitivity Predictors of Alprazolam Withdrawal in Panic Disorder
ROY-BYRNE, P., RUSSO, J., POLLACK, M., STEWART, R., BYSTRISKY, A., BELL, J., ROSENBAUM, J., CORRIGAN, M. H., STOLK, J., RUSH, A. J., et al. (2003) · Psychological Medicine · doi:10.1017/s0033291703007402 · Cited by 11
The prevention of convulsions during benzodiazepine withdrawals.
(1990) · Europe PMC (PubMed Central) · Cited by 7
The Drug Treatment of Anxiety and Panic Disorder
Rickels, K., Case, W. G., & Schweizer, E. (1988) · Stress Medicine · doi:10.1002/smi.2460040408 · Cited by 6
BENZODIAZEPINES AND CONVULSIONS
Robertson, R., Skidmore, C. A., & Roberts, J. J. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90145-6 · Cited by 6
O'Connor, K., Bélanger, L., Aardema, F., Pérodeau, G., & Harel, F. (2012) · Journal of Substance Use · doi:10.3109/14659891.2010.513755 · Cited by 4
Benzodiazepines Dependence: Addiction to Legally Prescribed Substances
S. Anna Gandra, S., D Almeida, A. L., & M. Teixeira, Z. (2019) · Journal of Forensic Psychology · doi:10.35248/2475-319x.19.4.149 · Cited by 4 · cited 1×
“Despite recommendations, the number of prescriptions has increased exponentially over the last 30 years [17].”
Background(2018) · Europe PMC (PubMed Central) · Cited by 4
Psychological and Pharmacological Treatments for Insomnia: Blending for Patient Benefit
Morgan, K. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101415 · Cited by 3 · cited 1×
“BZDs are effective in the treatment of anxiety disorders [2–4] and insomnia [5,6].”
BackgroundAcceptance and Commitment Therapy for Insomnia: A Pilot Study
Rafihi-Ferreira, R., Neto, F. L., Morin, C., Toscanini, A., Borges, D. S., Brasil, I. S. P. D. S., Gallinaro, J. G., Conway, S. G., & Hasan, R. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.11.1030 · Cited by 2
Research works printed but not linked: 5
- National Institute of Clinical Excellence British National Formulary Group B. Press P. National Institute of Clinical Excellence London, UK 2017
- Canadian Agency for Drugs and Technology in Health Discontinuation Strategies for Patients with Long-Term Benzodiazepine Use: A Review of Clinical Evidence and Guidelines Available online: http://www.ncbi.nlm.nih.gov/pubmed/26290934 (accessed on 9 March 2021) 26290934
- Morin C.M. Insomnia: Psychological Assessment and Management Guilford Press New York, NY, USA 1993
- Barlow D. Crask M. Mastery of Your Anxiety and Panic Graywind Press Albany, NY, USA 1989
- Hayes S.C. Strosahl K. Wilson K.G. Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change Guilford Press New York, NY, USA 1999
Cited by
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“157,166 Clinicians can also consider consulting with psychiatrists or sleep medicine specialists to help guide treatment plans.”
Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders
Morcuende, Á., García‐Gutiérrez, M. S., Tambaro, S., Nieto, E. O., Manzanares, J., & Femenía, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.866052 · Cited by 50
Ellis, J. G., Ferini‐Strambi, L., García-Borreguero, D., Heidbreder, A., O’Regan, D., Parrino, L., Selsick, H., & Penzel, T. (2023) · Healthcare · doi:10.3390/healthcare11050716 · Cited by 56
“6% of the French population took benzodiazepines for sleep problems [116].”
BackgroundZhu, X., Luo, T., Wang, D., Zhao, Y., Jin, Y., & Yang, G. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.165732 · Cited by 45
Gkintoni, E., & Νικολάου, Γ. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21081110 · Cited by 43
“The affective component uses various therapeutic methods designed to cope with emotions [62–64].”
Background
Metadata
- Authors
- Chapoutot, M., Peter-Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R., Siclari, F., Nicolas, A., Lemoine, P., Higgins, S., Bourgeois, A., Vallet, G. T., Anders, R., Ounnoughene, M., Spencer, J., Meloni, F., & Putois, B.
- Affiliations
- Lyon 1 Université (FR)
- Association Nationale de Promotion des Connaissances sur Le Sommeil, 69001 Lyon, France
- Xceltranslate, 06000 Nice, France
- Institut de Psychologie Contextuelle, Montreal, QC H2Y 2S9, Canada
- Centre Hospitalier Universitaire Vaudois (CH)
- Centre Hospitalier Annecy Genevois (FR)
- University of Geneva (CH)
- Centre National de la Recherche Scientifique (FR)
- Université Lumière Lyon 2 (FR)
- Cabinet de Psychiatrie du Plateau de Haye, 54320 Maxéville, France
- UniDistance Suisse (CH)
- Corresponding author
- Putois, Benjamin
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2021-09-28
- Volume
- 18
- Issue
- 19
- Pages
- 10222
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC8508349
- OpenAlex
- W3204225041
- Cited by
- 59
- References
- 158
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 10 · 2023: 17 · 2022: 3
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- Le dépôt institutionnel (Université du Québec à Trois-Rivières) (submittedVersion)
- IRIS (submittedVersion, cc-by)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- FONDATION ALCEA (XXX)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
- Keywords
- benzodiazepine discontinuation, cognitive behavioral therapy, acceptance and commitment therapy, insomnia, anxiety disorders, benzodiazepine withdrawal, benzodiazepine dependence, substance use disorders, chronic sleep disorders
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Humans, Sleep Initiation and Maintenance Disorders, Substance Withdrawal Syndrome, Cognitive Behavioral Therapy, Acceptance and Commitment Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.